Drug Development Status Report
This is a practical guide to building a status report for a drug development project — a periodic summary of progress, issues and next steps, adapted to the realities of developing a pharmaceutical product through regulatory stages.
What a Status Report is
A status report is a periodic summary of progress, issues and next steps. For the full concept and how it works in general, see Status Report. On a drug development project it plays the same role, tuned to this kind of work.
Why it matters for a Drug Development project
Drug Development projects live or die on developing a pharmaceutical product through regulatory stages. A well-built status report gives the team a shared, explicit reference for exactly that — reducing ambiguity, aligning stakeholders, and making problems visible early enough to act. Skipping it, or doing it generically, is how drug development projects drift into avoidable delay and cost.
What to include
- Overall RAG status
- Progress vs plan
- Key risks and issues
- Budget/schedule health
- Decisions needed
Drug Development-specific considerations
Tailor the status report to the risks that most often derail drug development projects:
- Regulatory approval delays
- Trial/validation failures
- Strict GxP compliance
Example
On a real drug development project, the status report would be shaped by developing a pharmaceutical product through regulatory stages. In particular, it should explicitly account for the project’s biggest risks — regulatory approval delays, trial/validation failures, strict GxP compliance — rather than treating them as afterthoughts.